Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Net Cash Flow (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Net Cash Flow for 3 consecutive years, with $19.2 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Net Cash Flow rose 188.9% year-over-year to $19.2 million, compared with a TTM value of $31.2 million through Dec 2021, up 126.24%, and an annual FY2024 reading of -$19.8 million, down 191.78% over the prior year.
  • Net Cash Flow was $19.2 million for Q4 2021 at Black Diamond Therapeutics, up from $9.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $202.5 million in Q1 2020 and bottomed at -$293.2 million in Q2 2020.
  • Average Net Cash Flow over 3 years is $1.3 million, with a median of $2.1 million recorded in 2019.
  • Peak annual rise in Net Cash Flow hit 3040.26% in 2020, while the deepest fall reached 5685.46% in 2020.
  • Year by year, Net Cash Flow stood at $76.0 million in 2019, then crashed by 128.41% to -$21.6 million in 2020, then surged by 188.9% to $19.2 million in 2021.
  • Business Quant data shows Net Cash Flow for BDTX at $19.2 million in Q4 2021, $9.3 million in Q3 2021, and $23.2 million in Q2 2021.